To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Ace Report Cover

AAOS 2016: Liposomal vs standard bupivacaine in TKA; no difference in analgesic efficacy

Download
Share
Reprints
Cite This
About
+ Favorites
Share
Reprints
Cite This
About
+ Favorites
Ace Report Cover
March 2016

AAOS 2016: Liposomal vs standard bupivacaine in TKA; no difference in analgesic efficacy

Vol: 5| Issue: 3| Number:34| ISSN#: 2564-2537
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A

Periarticular Liposomal Bupivacaine Offers No Benefit Over Bupivacaine in Total Knee Arthroplasty

Contributing Authors:
P Alijanipour T Tan C Matthews JR Viola JJ Purtill RH Rothman J Parvizi M Austin

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

CONFERENCE ACE REPORTS

This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.

Synopsis

162 patients scheduled for primary total knee arthroplasty were randomized to periarticular injections with either liposomal bupivacaine or standard bupivacaine. Pain scores and narcotic consumption were recorded over the first 4 postoperative days while function and health-related quality of life were assessed at 4-6 weeks postoperatively. Results demonstrated no significant difference between gr...

CME Image

Did you know that you’re eligible to earn 0.5 CME credits for reading this report!

LEARN MORE

Join the Conversation

Please Login or Join to leave comments.